Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2008-4-21
pubmed:abstractText
In Fabry disease, end-stage renal disease (ESRD) and severe neurologic and cardiac complications represent the leading causes of late morbidity and mortality. A comprehensive Italian nationwide survey study was conducted to explore changes in cardiac status and renal allograft function in Fabry patients on renal replacement therapy (RRT) and enzyme replacement therapy (ERT).
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1460-2385
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
23
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1628-35
pubmed:meshHeading
pubmed-meshheading:18057066-Adult, pubmed-meshheading:18057066-Aged, pubmed-meshheading:18057066-Cross-Sectional Studies, pubmed-meshheading:18057066-Fabry Disease, pubmed-meshheading:18057066-Female, pubmed-meshheading:18057066-Humans, pubmed-meshheading:18057066-Hypertrophy, Left Ventricular, pubmed-meshheading:18057066-Isoenzymes, pubmed-meshheading:18057066-Italy, pubmed-meshheading:18057066-Kidney Failure, Chronic, pubmed-meshheading:18057066-Kidney Transplantation, pubmed-meshheading:18057066-Male, pubmed-meshheading:18057066-Middle Aged, pubmed-meshheading:18057066-Prospective Studies, pubmed-meshheading:18057066-Recombinant Proteins, pubmed-meshheading:18057066-Registries, pubmed-meshheading:18057066-Renal Replacement Therapy, pubmed-meshheading:18057066-Ventricular Dysfunction, Left, pubmed-meshheading:18057066-alpha-Galactosidase
pubmed:year
2008
pubmed:articleTitle
Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.
pubmed:affiliation
Department of Nephrology and Dialysis, Infermi Hospital, via Settembrini 2, 47900 Rimini, Italy. rmignani@auslrn.net
pubmed:publicationType
Journal Article, Multicenter Study